

Press release for immediate release

The MyPebs study: towards a new strategy for breast cancer screening?



30 August 2021 - The aim of MyPeBS (*My Personal Breast Cancer Screening*) is to evaluate a breast cancer screening strategy based on individual risk. A total of 27 international partners are participating in MyPeBS. The clinical study is taking place in six countries (Belgium, France, Italy, the United Kingdom, Israel, Spain) and is coordinated by Unicancer (France). In Belgium it is being conducted at 10 hospitals and coordinated by the Jules Bordet Institute.

The limits of current screening

The present screening programme for breast cancer (“Mammotest”) proposes the same screening for all women aged between 50 and 69 on the basis of a single risk factor: age. Yet the risk of cancer varies from one woman to another depending on a number of factors: family history, personal antecedents, lifestyle, genetic constitution. Although the current screening is effective (fewer aggressive therapies, reduced mortality), it does have disadvantages: overdiagnosis (finding and treating tumours that would not have posed a problem), interval cancers (cancers undiagnosed between 2 routine screenings), false positives (women called back for further tests that do not reveal a cancer).

MyPeBS, towards a personalised breast cancer screening

Today we are able to evaluate individual risk, in a standardised manner that is both reliable and reproducible. MyPeBS (*My Personal Breast Cancer Screening*) is the first European clinical study that aims to evaluate the benefits of personalised screening with a frequency and procedures adapted to the individual risk of each woman. This new screening strategy that takes into account individual risk aims to increase the effectiveness of organised cancer screening while reducing the disadvantages. The study results will make it possible to propose European recommendations to improve organised screening. For the study as a whole in the five “recruiter” countries, 85 000 women volunteers aged between 40 and 70 who have never had breast cancer are invited to participate. In Belgium, 10 screening centres, mostly in hospitals, are participating in the project.

In practice, how to participate ?

Administrative conditions for participating:

- to be a woman aged between 40 and 70 (inclusive)
- to have health cover and a social security number (N° NISS)
- to have a mobile phone and e-mail address

Please note: this study **is not** for you if:

- you have a genetic mutation that places you at high risk of breast cancer (BRCA,...).
- you have already had breast cancer
- you have received irradiation of the chest wall (for a lymphoma)
- you have had an abnormal breast biopsy
- your last mammogram showed an abnormality that is being further investigated.

You meet the criteria and would like to know more about MyPeBS?

- ➔ Contact the CancerInfo (Cancer Foundation) call centre:
 - 0800 15 801 for French speakers (free number)
 - 0800 15 802 for Dutch speakers (free number)

Would you like to participate in MyPeBS?

- ➔ Contact the participating centre nearest you:
 - [Institut Jules Bordet](#) (1000 Brussels) - 02 541 30 53
 - [CHU St Pierre](#) (1000 Brussels) - 02 535 44 92
 - [CHU Brugmann](#) (1020 Laeken) - 02 477 38 46
 - [Hôpitaux Iris Sud - Site Ixelles](#) (1050 Ixelles) - 02 641 41 47 / 02 641 48 58
 - [UZ Brussel](#) (1090 Jette) - 02 477 53 34
 - [CHIREC DELTA](#) (1160 Auderghem) - 02 434 89 79
 - [Cliniques Universitaires St Luc](#) (1200 Woluwe Saint Lambert) - 02 764 18 18
 - [UZ Leuven](#) (3000 Leuven) - 016 34 69 65
 - [Centre de Sénologie Drs Crevecoeur](#) (4000 Liège) - 04 223 07 10
 - [Centre Hospitalier de Wallonie Picarde](#) (7500 Tournai) - 069 333 050

For more information on the MyPeBS study

- ➔ Visit www.mypebs.eu
- ➔ Watch the short video below:
 - English : <https://youtu.be/ZQQqMgOPX7k>
 - French: <https://youtu.be/RwOQLtcmLo8>
 - Dutch: <https://youtu.be/eiMfigZJT7Q>

This project is financed by the European Union's Horizon 2020 programme for research and innovation under grant agreement n° 755394. In Belgium it is also being supported by the Foundation against Cancer

Press Contacts

Institut Jules Bordet

Ariane van de Werve

GSM : +32 486 17 33 26

E-mail : ariane.vandewerve@bordet.be

www.bordet.be

About the Jules Bordet Institute

An integrated multidisciplinary centre, unique in Belgium, the Jules Bordet Institute is an autonomous hospital devoted exclusively to cancer.

For 80 75 years, the Jules Bordet Institute has been providing its patients with diagnostic and therapeutic strategies at the forefront of progress to prevent, detect and actively combat cancer. The Institute pursues three missions: care, research and teaching. Its international reputation attracts the world's leading cancer experts. Its spirit of innovation has enabled it to participate in the development and discovery of major new methods of diagnosis and treatment with the aim of bringing the findings to the patient as rapidly as possible.

In May 2018, the Jules Bordet Institute received official accreditation and designation from the OECI (Organisation of European Cancer Institutes) as a "Comprehensive Cancer Centre", a quality label reserved for multidisciplinary cancer care institutions whose activities include research and teaching. The only Comprehensive Cancer Center accredited by the OECI in Belgium.

The Jules Bordet Institute is a member of the Iris and Université Libre de Bruxelles hospital networks. With its 160 beds dedicated exclusively to cancer patients, every year the Institute treats more than 6,000 in-patients., 15,000 out-patients and provides 84,000 consultations. To effectively meet future demographic and scientific developments, a new Bordet Institute is being built on the ULB Anderlecht campus, next to the Erasmus Hospital. Inauguration is scheduled for the end of 2021.

www.bordet.be

About the Friends of the Bordet Institute

For more than 50 years, "The Friends of the Bordet Institute" have been financing research against cancer research at the Jules Bordet Institute, the reference centre in the fight against cancer in Belgium and abroad. As the Institute's biggest private donor, it has given close to 13 million euros to the Institute in the past five years.

Considerable progress has been made in the field of oncology in recent years. Our understanding of the biological origin of cancer is growing all the time. Whereas 10 years ago we spoke of the microscopic analysis of tumours, today we speak of genetic profile, of sequencing, etc. Dozens of new molecules and markers have been developed, permitting the advent of personalised treatment. This progress has to a large extent been

Rue Héger-Bordetstraat 1, B-1000 Bruxelles/Brussel

T + 32 (0)2 541 31 11, F + 32 (0)2 541 35 06, BELFIUS: BE72 0910 0972 7816, www.bordet.be

Institut Jules Bordet, Association Hospitalière de Bruxelles régie par la loi du 8 juillet 1976
Jules Bordet Instituut, Ziekenhuisvereniging van Brussel onderworpen aan de wet van 8 juli 1976



made possible through the extraordinary technological progress of recent years. But these new techniques that now enable us to probe the infinitesimally small are increasingly expensive.

For more than 50 years, the help of the "Friends" has enabled the Jules Bordet Institute to pursue its research using the most advanced technologies, thereby providing patients with the most innovative screening and treatment techniques. Techniques that generate life and hope.

By helping and supporting "The Friends of the Bordet Institute" you are participating in the many research programmes that they support and that all pursue a single aim: victory for life.

To find out more about the association The Friends of the Jules Bordet Institute, go to the website www.amis-bordet.be

To find out more about the "101 tables pour la vie", go to the website www.101tables.com